Article: HYBRIDON'S OLIGONUCLEOTIDES SHOW POTENT ADJUVANT ACTIVITY.

Hybridon, Inc. (AMEX: HBY), Cambridge, Mass., has presented preclinical results illustrating that its 2nd generation immunomodulatory oligonucleotide (IMO) compounds demonstrated potent adjuvant activity, inducing Th1-type mucosal immune responses in mice following oral administration. Th1-type immune responses are important in protecting against infectious diseases and boosting antibody formation.

"These results indicate the improved stability of our novel IMO structures in the gut facilitates increased immune responses," said Tim Sullivan, Ph.D., senior director of development programs for Hybridon. "The data support the potential use of IMO compounds as Th1 adjuvants ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!